

FDA Approves First Artificial Implantable Heart

BY ALICIA AULT

Associate Editor, Practice Trends

The Food and Drug Administration has given a limited approval to the first totally artificial implantable heart, Abiomed Inc.'s AbioCor.

The AbioCor was approved under a humanitarian device exemption. Under an HDE, the device has to show a "probable benefit," a less onerous standard than would be required under a premarket approval application, said Dr. Daniel Schultz, director of the FDA's Center for Devices and Radiological Health. The approval limits use of the device to no more than 4,000 patients each year.

Both the FDA and Danvers, Mass.-based Abiomed expect there to be a very limited patient population. The \$250,000 device is indicated in patients with severe right and left ventricular failure, who are not eligible for transplant and who have a life expectancy of less than 1 month. Patients also may have pulmonary hypertension refractory to pharmacologic management, significant aortic valve regurgitation, mechanical valve prosthesis, intractable life-threatening arrhythmias, ventricular septal rupture, or failed transplant.

Most likely, only men and larger women would be eligible to receive the 2-pound device.

In Abiomed's 14-patient study, patients were an average 6 feet tall and weighed 170-180 pounds, Dr. Bram Zuckerman, director of FDA's Division of Cardiovascular Devices, said in a briefing with reporters.

The AbioCor is the result of almost 30 years of research and development, much of which was supported by the National Heart, Lung, and Blood Institute.

"The approval of the totally implanted artificial heart is a significant milestone as there are few options for heart failure patients with the most severe form of the disease and who are in critical need," the NHLBI's director, Dr. Elizabeth G. Nabel, said in a statement.

The implanted system consists of an artificial heart, a battery, and two controllers that receive information via radio waves from an external controller and power source. Patients can be away from a power source for up to 1 hour—an important quality-of-life consideration that influenced the FDA's approval decision, Dr. Zuckerman said.

In Abiomed's original study—in 14 patients from 2001 to 2004—6 of the 12 patients who survived surgery were ambulatory and 4 made excursions outside of the hospital. One patient was discharged to home. The mean life span on AbioCor was 5 months, but the range was 53-512 days.

"Just being able to ambulate, to clearly communicate with loved ones, and to celebrate family events is, in the view of many patients and family members, a significant improvement in quality of life," Dr. Zuckerman said.

The FDA approval comes despite a 7-6 vote against approval by an FDA advisory panel in June 2005. The committee had concerns about clotting and stroke risk.

After the first five patients were implanted and died, Abiomed conducted au-

topies that led the company to slightly redesign the AbioCor, which was accepted by the FDA, said company chairman and CEO Michael R. Minogue in an interview. Anticoagulation continued to be a challenge in the next nine patients, however.

The company has learned that only patients who can tolerate anticoagulation therapy should receive the AbioCor, Mr. Minogue said. In a planned postapproval study, which will enroll all patients implanted with the device, the company will

determine how to best manage patients and whether it can appropriately train surgeons at new clinical sites.

The first implants will occur at Jewish Hospital in Louisville, Ky., where Dr. Laman Gray, director of the division of thoracic and cardiovascular surgery at the University of Louisville, and Dr. Rob Dowling, director of the heart transplant and cardiac assist devices program at Jewish Hospital, have implanted 7 of the original 14 devices since 2001.

Both Johns Hopkins Hospital, in Baltimore, and the Robert Wood Johnson University Hospital, in New Brunswick, N.J., also have entered into letters of intent to implant the AbioCor. Mr. Minogue said he expects training at these facilities to take at least 8-10 months.

The company aims to bring 5-10 centers on line. The AbioCor 2 is currently in development. It will be 30% smaller, have a different pump system, and will last up to 5 years, Mr. Minogue said. ■



Discover **Levemir**®:
a long-acting basal insulin
with a light touch

Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir® FlexPen®. FlexPen® is the world's #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations. Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005]. Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S. © 2006 Novo Nordisk Inc. 131007 September 2006

Levemir®
insulin detemir (rDNA origin) injection
Lighter years ahead

novo nordisk